Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma.

The median IOP significantly decreased from 19 mmHg at baseline to 14 mmHg at 12 months (p < 0.001), while the median glaucoma drug score showed no significant change, from 3 at baseline to 4 at 12 months (p = 0.562).

A positive correlation was observed between the duration of uveitic glaucoma and the change in IOP at 12 months (rho = 0.539, p < 0.01).

In the subgroup analysis restricted to eyes switched from ripasudil plus brimonidine eye drops to RBFC, IOP showed a decreasing trend (p = 0.057).

No drug-related adverse events were observed, except for transient conjunctival hyperemia.